|Support type:||Scholarships in Brazil - Post-Doctorate|
|Effective date (Start):||January 01, 2020|
|Effective date (End):||December 31, 2021|
|Field of knowledge:||Engineering - Materials and Metallurgical Engineering|
|Principal Investigator:||Marlus Chorilli|
|Grantee:||Rafael Miguel Sábio|
|Home Institution:||Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil|
Prostate cancer (PC) is one of the most non-contagious diseases that affects the male population in the world. Although clinically effective, the chemotherapy treatment with docetaxel (DTX) is associated with the development of resistance in more advanced stages of the disease. Beyond that, DTX presents low aqueous solubility and drawbacks related to its pharmacokinetics. Mesoporous silica nanoparticles have attracted great interest due to their high chemical stability, large surface area and tunable pores diameters and volumes, allowing the incorporation of large amounts of drugs, protecting them from deactivation and degradation processes besides avoids premature release acting as an excellent nanocarrier. In addition, the hydroxyls groups available on its surface allows the conjugation of molecules such as the monoclonal antibody cetuximab (CTE) which binds to the overexpressed Enhanced Growth Factor Receptor (EGFR) in many prostate tumors, representing a potential strategy for the treatment of prostate cancer associated to DTX. Taking into account all aforementioned, the goal of this research project consist on develop intelligent nanoplatforms based on mesoporous silica nanoparticles functionalized with CTE as DTX carriers to PC treatment. This proposal aims to overcome drawbacks as low internalization, premature release before to reach the region of interest, several side effects to the patient and low effectiveness of the current treatments. In order to evaluate these parameters, materials characterization and methods validation will be carried out as well as in vitro assays using PC-3 and DU145 cells line models and in vivo assays from animal model aiming to prove the efficacy of the new nanocarriers.